Skip to content
Synopulse
  • News
  • Editor’s Feature
  • NeuroPulse
  • Industry Trends
    • Market Access
    • Deals
    • Technologies
      • Cell & Gene Tx
      • Antibody
      • AI
      • MedTech
    • Legal, Antitrust & IP
    • Speciality
      • Neurology
      • Orthopaedics
      • Oncology
      • Cardiometabolic
      • Pediatrics
  • Regulatory
    • FDA Updates
    • EMA Updates
    • Global Compliance
    • About US

Coverage Decisions

Brensocatib faces ICER spotlight with strong case for clinical and economic value

November 3, 2025 by Shajini
CMS Sets National Pricing for Vesiflo’s inFlow Device, Expanding Access for Women With Permanent Urinary Retention

ICER pegs an ~$88K benchmark for brensocatib and spotlights evidence gaps shaping NCFB access.

Categories HTA, Market Access, News, Pricing and Reimbursement Tags Brensocatib, Coverage Decisions, ICER, Institute for Clinical and Economic Review, NCFB, non-Cystic Fibrosis, Reimbursement
Synopulse Weekly Pulse: Access Decisions, Regulatory Events & Market Dynamics, Week of Nov 24 2025

Synopulse Weekly Pulse – November 24, 2025

Read Now
  • AI
  • Antibody
  • Cardiometabolic
  • Cell & Gene Tx
  • Deals
  • Dealstreet
  • Device Approvals
  • Editor’s Feature
  • EMA Updates
  • FDA Updates
  • Global Compliance
  • HTA
  • Industry Trends
  • Legal, Antitrust & IP
  • Litigation, Law & Policy
  • Market Access
  • Market Pulse
  • MedTech
  • Monthly Insight's
  • Neurology
  • NeuroPulse
  • News
  • Oncology
  • Orthopaedics
  • Pediatrics
  • Pricing and Reimbursement
  • Regulatory
  • Weekly Pulse
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • July 2025
  • June 2025
  • February 2025
  • January 2025
  • October 2024
  • September 2024
Synopulse
Contact Us

Explore Synopulse

  • NeuroPulse
  • Deals
  • Market Access
  • Industry Trends
  • Regulatory

About

  • About Synopulse
  • Contact Us
  • Announcements
© 2026 Synopulse • Built with GeneratePress